Treatment for acute respiratory distress syndrome in adults: a narrative review of phase 2 and 3 trials.

Denise Battaglini Fabio Silvio Taccone Paolo PelosiPatricia R M Rocco

Published in: Expert opinion on emerging drugs (2022)

Identification of ARDS phenotypes, risk factors, heterogeneity, and pathophysiology may help to design clinical trials personalized according to ARDS-specific features, thus hopefully decreasing the rate of failed clinical pharmacologic trials. This concept is still under clinical investigation and needs further development.

Keyphrases

acute respiratory distress syndrome
extracorporeal membrane oxygenation
mechanical ventilation
risk factors
clinical trial
intensive care unit
open label
combination therapy